Last mentioned: Mar 20, 2026
Implementation
New pricing structures and stricter clinical criteria for reimbursement are expected to take effect.
Subsidy Cut Announcement
Government announces plans to slash subsidies for SCS devices based on findings that they 'don't work' for many patients.
Regulatory Review
The TGA and Department of Health initiate a formal review into the clinical efficacy of spinal cord stimulators.
Rising Adverse Events
Increased reporting of 'failed back surgery syndrome' and device-related injuries in Australian hospitals.
The public endorsement of medicinal cannabis by patients like Bilal Cassim for PTSD and insomnia highlights a significant shift in Australian healthcare toward cannabinoid therapies. This trend reflects a broader move toward alternative mental health treatments as the clinical and regulatory landscape continues to evolve.
The Australian government is moving to drastically reduce subsidies for spinal cord stimulators following evidence of severe patient injuries and a lack of clinical efficacy. This regulatory pivot marks a major shift in medical device reimbursement, prioritizing long-term safety over industry-led innovation claims.